Author/Authors :
Nassirtoosi, Mohssen tehran university of medical sciences tums - Department of Internal Medicine, تهران, ايران , Lak, Manije tehran university of medical sciences tums - Department of Internal Medicine, تهران, ايران , Karimi, Katayoun tehran university of medical sciences tums - Department of Internal Medicine, تهران, ايران , Managchi, Mohammadreza tehran university of medical sciences tums - Department of Internal Medicine, تهران, ايران , Samimi-rad, Katayoun tehran university of medical sciences tums - Department of Internal Medicine, تهران, ايران , Abdollahi, Alireza tehran university of medical sciences tums - Department of Pathology, تهران, ايران , Shahsiah, Reza tehran university of medical sciences tums - Department of Pathology, تهران, ايران
Abstract :
In the history of hemophilia treatment, the 1940s were a time of transition from primitive, conven-tional attempts to control bleeding episodes to transfusion therapy, which represented a major accom- plishment,1,2 Even though the discovery of cryopre- cipitate and factor concentrates and lyophilized con- centrates led to great improvements in both longevity and quality of life for persons with hemophilia, at the same time a group of tragic setbacks were reported,2 3 These important negative consequences were complica- tions resulting from transmission of hepatitis B virus (HBV), hepatitis C virus (HCV), and human immu- nodeficiency virus (HIV). It was discovered that virtu- ally all hemophilia patients exposed to non-heat-treated factor were HCV positive, and over 50% of hemophilia patients in the United States had HIV seroconversion, and 5% to 10% of such patients became chronic carriers of hepatitis B.3 7
